The hematopoietic effect of epotin (Recombinant human erythropoietin- α) on maintenance hemodialysis end-stage kidney disease patients

Transplantation Proceedings

Volumn 42, Issue 3, 2010, Pages 753-759

  Al Shohaib, S ^a   Shaker, D S ^b   Ghaedi, B B ^b   Alyarim, M ^a   Emara, S ^a   Behairy, M ^a  

^a King Abdul Aziz University Hospital Kingdom of Saudi Arabia   (United Arab Emirates)

^b Dubai Research Center   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ERYTHROPOIESIS; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; RENAL REPLACEMENT THERAPY;

ANEMIA; COMBINED MODALITY THERAPY; EPOETIN ALFA; ERYTHROPOIESIS; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 77955484496     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.02.056     Document Type: Conference Paper

References (33)

1. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure Nephrol Dial Transplant 19 Suppl 2 2004 ii1
2. IV. NKF-K/DOQI Clinical Practice Guidelines for Anaemia of Chronic Kidney Disease: update 2000 Am J Kidney Dis 37 2001 S182
3. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure Nephrol Dial Transplant 14 suppl 5 1999 19
4. F. Locatelli Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure Nephrol Dial Transplant 19 suppl 2 2004 16
5. K.S. Brimble, C.G. Rabbat, and P. McKenna Protocolized anaemia management with erythropoietin in hemodialysis patients: a randomized controlled trial J Am Soc Nephrol 14 2003 2654
6. J. Rossert, N. Casadevall, and K.U. Eckardt Antierythropoietin antibodies and pure red cell aplasia J Am Soc Nephrol 15 2004 398
7. Souqiyyeh MZ, Shaheen FAM: Attitude of physicians toward Erythropoietin supplementation in hemodialysis patients. Saudi J Kidney Dis Transplant (in press)
8. M.Z. Souqiyyeh, and F.A.M. Shaheen Attitude of physicians toward iron supplementation in hemodialysis patients treated with erythropoietin Saudi J Kidney Dis Transplant 14 2003 134
9. W.H. Horl, and Y. Vanrenterghem Optimal Treatment of Renal Anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin Nephrol Dial Transplant 20 suppl 3 2005 iii25
10. R.L. Pisoni, J.L. Bragg-Gresham, and E.W. Young Anaemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 44 2004 94
11. F.A.M. Shaheen Guidelines to the treatment of anaemia in chronic kidney disease in Saudi Arabia 2006 Accessed March 20 www.scot.org.sa/Saudi Guidelines/Saudi Guidelines of Anaemia 2006.doc 2008
12. H.B. Maiz, E. Abdelrrahim, and K. Zouaghi Anaemia and end stage renal disease in the developing world Artif Organs 26 2002 760
13. E.E. Abbas, N. Afioni, and J. Alwakeel The new rHuEpo alpha (Epotin) in the management of anaemia of end stage renal disease in patients on maintenance hemodialysis Transplant Proc 36 2004 1805
14. W. Jelkmann Recombinant EPO production- points the nephrologists should know Nehrol Dial Transplant 22 2007 2749
15. Committee for Medicinal Products for Human Use: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues EMEA/CHMP/BMWP/42832/2005 2006
16. A. Wiecek, and A. Mikhail European regulatory guidelines for biosimilars Nephrol Dial Transplant 21 suppl 5 2006 v17
17. G. Sunder-Plassmann, and W.H. Hori Erythropoietin and iron Clin Nephrol 47,3 1997 141
18. J. Cohen Statistical Power Analysis for the Behavioural Sciences 2nd Ed 1988 Lawrence Erlbaum Associates Hillsdale, NJ
19. J.W. Eschbach The future of r-HuEPO Nephrol Dial Transplant 10 suppl 2 1995 96
20. D. Cotter, M. Thamer, and K. Narasimhan Translating epoetin research into practice: the role of government and the use of scientific evidence Health Aff (Millwood) 25 2006 1249
21. J.B. Wish The economic realities of erythropoiesis-stimulating agent therapy in kidney disease Kidney Int 70 2006 S21
22. H. Schellekens How similar do 'biosimilars' need to be? Nat Biotechnol 22 2004 1357
23. S.D. Roger Biosimilars: how similar or dissimilar are they? (Review Article) Nephrology 11 2006 4 341
24. C. Combe, R.L. Tredree, and H. Schellekens Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins Pharmacotherapy 25 2005 954
25. P.L. Storring, R.J. Tiplady, and D.R. Gaines Epoetin- and -β differ in their erythropoietin isoform compositions and biological properties Br J Haematol 100 1998 79
26. S. Deechongkit, K.H. Aoki, and S.S. Park Biophysical comparability of the same protein from different manufacturers: a case study using epoetin- from Epogen and Eprex J Pharm Sci 95 2006 1931
27. A.K. Singh New Erythropoietin. Medscape Nephrology, 2008 http://www.medscape.com/viewarticle/567348 Accessed December 20, 2008
28. A. Singh Gaps in the quality and potential safety of biosimilar epoetins in the developing world: an international survey Program and abstracts of Renal Week 2006: American Society of Nephrology Annual Meeting November 14-19, 2006 San Diego California
29. K.-U. Eckardt, and N. Casadevall Pure red-cell aplasia due to antierythropoietin antibodies Nephrol Dial Transplant 18 2003 865
30. N. Casadevall, J. Nataf, and B. Viron Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N Engl J Med 346 2002 469
31. B. Sharma, F. Bader, and T. Templeman Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX Eur J Hosp Pharm 5 2004 86
32. C.L. Bennett, S. Luminari, and A.R. Nissenson Pure red-cell aplasia and epoetin therapy N Engl J Med 351 2004 1403
33. R. Dham, H. Kandil, and A. Helmi Three years epotin pharmacovigilance report Ras AL Kaima May 2006 Data on file